Bioengineering approaches to understand, model and modify healthy and pathological CNS (NET-CNS)

Date and Venue
Friday 09/05/2025 · 09:00h – 16:00 h
Sala Baobab, Tower I, Floor 11 (PCB)

The first workshop on May 9th will focus on will focus on exploring the molecular and cellular mechanisms of neurodegeneration and CNS pathology, as well as emerging therapies and prevention strategies. The event will feature two plenary lectures by leading external experts, along with a series of presentations by IBEC researchers.  

Amaia Arranz (Achucarro Basque Center for Neuroscience) – Investigating how APOE variants influence astrocyte function in Alzheimer’s disease using humanized in vitro models and chimeric mice.

Salvador Ventura (Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona) – Exploring protein folding, misfolding, and aggregation in Parkinson’s and other neurodegenerative diseases.

We will also have three presentations from IBEC researchers working in the field and a final roundtable discussion on how these novel concepts and approaches can drive new therapeutic strategies and prevention for CNS disorders.

Schedule programme:

9:00 – Registration

9:20 – Welcome from Network Coordinator

9:30 – Mariano Martín, IBEC, “Amyloids ‘at the border’: deep mutagenesis and random sequence extension reveal an incomplete amyloid-forming motif in Bri2 that turns amyloidogenic upon C-terminal extension”

10:00 – Invited speaker: Salvador Ventura, Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona, “A structure-based approach to tackle protein aggregation in Parkinson’s disease”

11:00 – Coffee Break and Networking

11:30 – Invited speaker: Amaia Arranz, Achucarro Basque Center for Neuroscience, “Divergent Effects of APOE3 and APOE4 Human Astrocytes on Key Alzheimer’s Disease Hallmarks in Chimeric Mice”

12:30 – Roundtable moderated by network chairs to debate the issues discussed

13:30 – Lunch break

14:30 – Amayra Hernández, IBEC, “Dynamics of Axonal Degeneration in Alzheimer’s Disease Induced by Tau or Amyloid Beta Aggregation”

15:00 – Karolina Zimkowska, IBEC, “Neuronal Activity and p-Tau: Lessons from Primary Cultures to Cortical Organoids Modeling FTLD-17”

15:30 – Closing remarks and end of the workshop

---

Plenary talks details:

Amaia Arranz (Achucarro Basque Center for Neuroscience)

Divergent Effects of APOE3 and APOE4 Human Astrocytes on Key Alzheimer’s Disease Hallmarks in Chimeric Mice

Despite strong evidence supporting that both astrocytes and apolipoprotein E (APOE) play crucial roles in the pathogenesis and progression of Alzheimer’s disease (AD), the impact of astrocytes carrying different APOE variants on key AD pathological hallmarks remains largely unknown. To explore such effects in a human relevant context, we generated a chimeric model of AD. We transplanted isogenic APOE3 or APOE4 human induced pluripotent stem cell (hiPSC)-derived astrocyte progenitors into neonatal brains of AD model mice. We show that at five to six months after transplantation, transplanted cells have differentiated into mature astrocytes (h-astrocytes) that often integrate in upper layers of one cortical hemisphere. APOE3 and APOE4 h-astrocytes differentially express and secrete the APOE protein, which binds to Aβ plaques with an isoform-dependent affinity. Remarkably, APOE3 h-astrocytes ameliorate Aβ pathology, Tau pathology and neuritic dystrophy. In contrast, APOE4 h-astrocytes aggravate these AD processes. Moreover, APOE3 and APOE4 h-astrocytes modulate microglia responses to Aβ pathology in opposite ways. APOE4 h-astrocytes enhance microglia clustering around Aβ plaques and exacerbate DAM state whereas APOE3 h-astrocytes reduce microglia clustering and induce a more homeostatic state on plaque-associated microglia. These findings highlight a critical contribution of h-astrocytes not only to Aβ pathology but also to other key AD hallmarks in chimeric mice. In addition, our findings reveal that h-astrocytes with different APOE variants and the different forms of APOE they secrete have a crucial role in AD progression.

Salvador Ventura (Institut de Biotecnologia i Biomedicina, Universitat Autònoma de Barcelona)

A Structure-Based Approach to Tackle Protein Aggregation in Parkinson’s Disease

α-Synuclein aggregation drives neurodegeneration in Parkinson’s disease (PD). We identified peptides that selectively bind to toxic α-synuclein oligomers and fibrils with high affinity while sparing the functional monomer. These peptides effectively inhibit aggregation and prevent oligomer-induced cell damage. Human peptide candidates with strong anti-aggregation and detoxifying properties were discovered, and the best in vitro candidate alleviated motor symptoms in a PD animal model. Structural studies mapped their binding region, showing that mutations or deletions in this site eliminate α-synuclein aggregation and toxicity. This insight led to the development of conformation-specific nanobodies and monoclonal antibodies that block amyloid formation, providing a novel therapeutic and diagnostic strategy for PD.

 

Date and Venue
Friday 23/10/2025 · 09:00h – 16:00 h
Baobab room, Torre I, Floor 11, Parc Científic de Barcelona (PCB)

This second workshop on October 23^th will focus on emerging neurotechnologies to interface with the CNS, including innovative strategies to record, stimulate, and modulate neural activity for both fundamental research and therapeutic interventions. The event will feature three lectures by leading experts: 

John Rogers (Northwestern University, Chicago) developing flexible and bio-integrated electronic devices to monitor health, interface with the nervous system, and advance medical therapies. 

Josep Maria Font Llagunes (Institute for Research and Innovation in Health (IRIS-UPC), Barcelona) developing computational methods for the analysis and prediction of human movement, innovative robotic exoskeletons and wearable monitoring technology. 

Aureli Soria-Frisch (Starlab, Barcelona), Director of Neuroscience at Starlab, a deep tech company that develops wireless platforms and AI tools to find biomarkers to diagnose and treat brain disorders, with applications ranging from neurodevelopment to cognitive decline in aging. 

Programme

09:00 – Registration 

09:20 – Welcome from Network Coordinator 

09:30 – IBEC speaker: Nicolò Accanto, Nonlinear Photonics for Neuroscience Group, ” Advanced Two-Photon Microscopy for Decoding Neuronal Circuits “  

10:00 – Invited speaker: John Rogers, Northwestern University, Chicago, “Bioelectronic Systems as Neural Interfaces” 

11:00 – Coffee Break and Networking 

11:30 – Invited Speaker: Aureli Soria-Frisch, Starlab, Barcelona, “From Starlab to Neuroelectrics, a neurotechnology transfer success case” 

12:30 – IBEC speaker: Mònica Mir, Nanobioengineering Group, “Integrated sensors in humanized models on a chip to study neurodegeneration” 

13:00 – Lunch Break 

14:15 – Invited speaker: Josep M. Font-Llagunes, Institute for Research and Innovation in Health (IRIS-UPC), “From Biomechanics to Clinical Impact: Exoskeleton and Monitoring Technologies in Neurorehabilitation” 

15:15 – IBEC speaker: Silvia Pittolo, Nanoprobes and Nanoswitches group, “Exploiting new technologies to read and control brain cells and circuits in real time” 

15:45 – End of the Workshop 

---

Plenary talks details:

Bioelectronic Systems as Neural Interfaces

John Rogers, Northwestern University, Chicago

Advanced electronic/optoelectronic systems constructed in classes of materials that enable intimate integration with soft tissues of the brain and the peripheral nervous system will accelerate progress in neuroscience research; they will also serve as the foundations for new approaches in regenerative medicine and in the treatment of neurodegenerative disease. Specifically, capabilities for injecting miniaturized electronic elements, light sources, photodetectors, multiplexed sensors, programmable microfluidic networks and other components into precise locations of the deep brain or for softly laminating them onto the surfaces of the spinal cord or peripheral nerves will open up unique and important opportunities in stimulating, inhibiting and monitoring neural circuit behaviors. This presentation will describe concepts in materials science and assembly processes that underpin these types of technologies, in 1D, 2D and 3D architectures. Examples include ‘cellular-scale’ optofluidic neural probes for small animal model research, 3D mesoscale networks for study of neural signal propagation in organoids and bioresorbable electrical stimulators for neuroregeneration.

From Biomechanics to Clinical Impact: Exoskeleton and Monitoring Technologies in Neurorehabilitation

Josep M. Font-Llagunes is Full Professor of Mechanical Engineering at Universitat Politècnica de Catalunya (UPC) and director of the BIOMEC Lab at the Institute for Research and Innovation in Health (IRIS-UPC)

Exoskeletons and other assistive devices are becoming key technologies in advanced therapies for neurorehabilitation. Their development and clinical use require a solid understanding of human movement and its interaction with wearable devices, which can be explored through biomechanical simulation. This lecture will discuss how personalized biomechanical models can support the design and control of exoskeletons, enabling more effective and individualized therapies. Recent clinical investigations on bilateral and monoarticular lower-limb exoskeletons for gait rehabilitation in individuals with spinal cord injury and stroke will be presented. In addition, results from a clinical study using an IMU-based wearable system to monitor arm kinematics in pediatric patients with muscular dystrophy will be discussed. Together, these examples illustrate how neurorehabilitation technologies, informed by biomechanical simulation, can help clinicians improve therapy personalization, monitor rehabilitation outcomes, and maximize functional recovery.

Friday 27/02/2026 · 09:00h – 13:00 h 

Baobab room, Torre I, Floor 11, Parc Científic de Barcelona (PCB) 

This third NET-CNS workshop, taking place on February 27th, will focus on overcoming therapeutic barriers in CNS disorders, with particular emphasis on delivery strategies, biological interfaces, and translational challenges. 

The event will feature three lectures by leading experts in the field: 

• Cristina Fornaguera, Professor of Bioengineering at the NanoTherapies Lab, Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL) — her research focuses on nanotechnology-based therapeutic systems and advanced drug delivery strategies across biological barriers. 

• Eloi Montañez, Associate Professor, Department of Physiological Sciences, Faculty of Medicine and Health Sciences, University of Barcelona (UB) — an expert in cell signaling, vascular biology, and endothelial function relevant to CNS and neurovascular interfaces. 

• Meritxell Teixidó, CEO & CSO, Gate2Brain SL, a Barcelona-based biotech developing peptide-based delivery technologies to transport therapeutics across the blood–brain barrier for CNS and oncology applications 

Programme 

9:00 – Registration ​ 

09:20 – Welcome from Network Coordinator ​ 

09:30 – IBEC speaker: Daniel Gonzalez-Carter, Molecular Bionics group Group. “Exploiting the physiology of the BBB to target therapies to the brain.​” 

10:00 – Invited speaker: Cristina Fornaguera, NanoTherapies Lab, Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL). “From Bench to Brain: Polymeric Nanoparticles for Controlled Brain Delivery”​ 

10:40 – Coffee Break and Networking ​ 

11:10 – Invited Speaker: Meritxell Teixidó, Gate2bBrain​. “Gate2Brain blood-brain barrier shuttle peptides: From discovery to applications and going beyond small molecules.” 

11:50 – Invited Speaker: Eloi Montañez, IDIBELL Department of Physiological Sciences 

Faculty of Medicine and Health Sciences, University of Barcelona. “Linking TDP-43 to Vascular Degeneration and Neuroinflammation” 

12:30 – IBEC speaker: Anna Lagunas, Nanobioengineering group​. “A BBB-on-a-chip (BBB-oC) with integrated micro-TEER to evaluate brain drug delivery”. 

13:00 – End of Workshop​ 

Plenary talk details

Cristina Fornaguera (NanoTherapies Lab, Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL) 

“From Bench to Brain: Polymeric Nanoparticles for Controlled Brain Delivery” 

Delivering therapeutics to the brain remains one of the major challenges in nanomedicine due to the presence of highly selective biological barriers, particularly the blood–brain barrier (BBB). Over the past decade, my research has focused on the rational design of polymeric nanocarriers capable of navigating these barriers to enable controlled and targeted delivery of both small-molecule drugs and nucleic acid–based therapeutics to the central nervous system. 

In this talk, I will present a journey from polymer chemistry and nanoparticle engineering at the bench to preclinical brain delivery applications. I will discuss how polymer composition, nanoparticle architecture, surface functionalization, and manufacturing strategies critically determine nanoparticle stability, biological identity, and interaction with physiological barriers. Particular emphasis will be placed on polymeric nanoparticles prepared by nano-emulsion templating and on poly(β-amino ester)–based systems as versatile platforms for brain-targeted delivery. 

Using selected examples, I will illustrate how these nanocarriers can be engineered to cross the BBB after systemic administration, achieve controlled drug release, and deliver RNA cargos—such as mRNA or other therapeutic nucleic acids—while preserving bioactivity and minimizing off-target effects. Advanced in vitro and in vivo models are used to unravel structure–function relationships and to bridge the gap between formulation design and biological performance. 

Overall, this presentation highlights how a deep understanding of nanoparticle–barrier interactions enables the translation of polymeric nanomedicines from bench to brain, opening new opportunities for the treatment of neurological and neurodegenerative diseases. 

Meritxell Teixidó (Gate2bBrain). 

“Gate2Brain blood-brain barrier shuttle peptides: From discovery to applications and going beyond small molecules.” 

Gate2Brain shuttle peptides represent salvage for new or previously rejected CNS drug candidates by providing a way to cross the blood-brain barrier (BBB).  

Gate2Brain technology consist on a toolbox of peptides able to cross the BBB and carry compounds covalently attached (including small molecules, peptides, proteins, antibodies, plasmids, siRNA or mRNA loaded nanoparticles, etc…) that cannot cross this barrier unaided. They have proofed to carry these cargoes in vitro and in vivo. These peptide shuttles use the existing transport mechanisms at the BBB without affecting the normal functioning of these mechanisms and preserving brain homeostasis. 

By improving the delivery of therapeutic candidate to the CNS, we will ensure immediate impact in many CNS diseases patients. In addition, in a broader perspective, Gate2Brain technology may help to repurpose existing therapies previously rejected because of difficulty to reach the brain, accelerating the translation towards clinical development. Gate2Brain will also result in the application of lower concentrations of therapeutic agent, thereby significantly lowering systemic side effects and reducing the cost of the treatment. 

Gate2Brain peptides combine protease resistance, capacity to carry a wide range of cargoes thanks to their versatility, low production costs, and low immunogenic risk. They provide a non-invasive, non-antigenic, permeable, stable, soluble and receptor-specific way to transport drugs across the BBB and into the CNS. 

Eloi Montañez (IDIBELL Department of Physiological Sciences Faculty of Medicine and Health Sciences, University of Barcelona) 

“Linking TDP-43 to Vascular Degeneration and Neuroinflammation” 

Defective vascular growth and loss of vessel stability are increasingly recognized as contributors to neurodegenerative disease. TAR DNA-binding protein 43 (TDP-43), a central regulator of gene expression, is well known for its pathogenic role in neurons; however, its contribution to vascular degeneration and neuroinflammation remains poorly defined. 

Here, we investigate the role of TDP-43 in endothelial cells using inducible, cell type-specific knockout mouse models. We show that endothelial TDP-43 is essential for sprouting angiogenesis, vascular barrier integrity, and blood vessel stability. Postnatal endothelial-specific deletion of TDP-43 resulted in retinal hypovascularization due to impaired endothelial proliferation and migration, while loss of TDP-43 in mature vessels disrupted the blood-brain barrier and triggered vascular degeneration. Notably, these vascular defects were accompanied by a robust neuroinflammatory response, characterized by activation of microglia and astrocytes. 

Mechanistically, TDP-43 deficiency disrupted the fibronectin matrix surrounding sprouting vessels and reduced β-catenin signaling in endothelial cells. Together, these findings establish TDP-43 as a critical molecular link between vascular degeneration and neuroinflammation, providing new insight into neurovascular mechanisms that may contribute to neurodegenerative disease 

This fourth workshop will focus on innovations in drug delivery systems, crossing the blood-brain barrier, local delivery of drugs, and engineered proteins to read brain activity.